powered by centersite dot net
Medications
Resources
Basic InformationLatest News
Lifesaving Drugs From Pfizer in Short Supply: FDALeading U.S. Doctors' Group Takes Aim at Rising Drug PricesU.S. Hospitals Still Prescribe Too Many Antibiotics: StudyBirth Control Pills Recalled Due to Danger of Unintended PregnancyNew Drugs Show Promise as First to Prevent MigraineMedication Adherence Up With Refill Synchronization ModelModified Vancomycin May Help Fight Bacterial ResistanceScientists Tweak Antibiotic to Boost Power Against 'Superbugs'New Cholesterol Fighting Meds Target Key GeneResearchers Say PDE5 Inhibitors Don't Cause MelanomaNearly a Third of Drugs Hit by Safety Issues After FDA ApprovalU.S. Moves to Avert Shortage of Yellow Fever VaccineOpioid Use by Iraq, Afghanistan War Vets Mirrors Rest of U.S.: StudyApril 29 Is National Prescription Drug Take Back DayERs Administering More Medications IntranasallyFDA Warns Against Children Taking Codeine, TramadolPhysicians Finding Ways to Work Around Cost of Rx MedicationsRuling Out Penicillin Allergy by Testing Inpatients Saves MoneyEpiPen Out-of-Pocket Costs More Than Doubled Over DecadeAACR: Regular Aspirin Use Linked to Lower Cancer MortalityFDA Approves Noctiva Nasal Spray for Nocturnal PolyuriaFDA Approves Odactra for House Dust Mite AllergiesHow Much Melatonin Is Really in That Supplement?Antidepressant Efficacy Varies for Depressive Symptom ClustersDo You Need an Antibiotic?'Off-Label' Antidepressants Common, But Where's the Evidence?Docs More Likely to Prescribe Antibiotics If Patients Expect ThemSimilar Adverse Event Risk for Typical, Atypical AntipsychoticsRx Adherence Reminders No More Effective at 'Fresh Start' DatesThink You're Allergic to Penicillin? Check AgainExcessive FDA Regulation Driving High Drug PricesOutcomes-Based Pricing Suggested for New, Costly DrugsPrices Skyrocket on Drugs Widely Used by Seniors: Report1 in 6 U.S. Adults Takes a Psychiatric Drug: StudyU.S. Doctors Still Over-Prescribing Drugs: SurveyWider Low-Dose Aspirin Use Would Save U.S. $692 Billion: StudyHealth Tip: Get the Facts About AntibioticsThese Medicines Often Send Americans to ERsHealth Tip: Be Aware of Drug and Food InteractionsCan Time-Release Capsules Replace Daily Pills?Prices of Generic Heart Failure Drugs Vary WidelyAmericans Fed Up With Soaring Drug Prices: HealthDay/Harris PollSaturday, Oct. 22 Is Drug Take Back DayHow Older People Can Head Off Dangerous Drug InteractionsCDC: Too Many Antibiotics Still Being Prescribed in U.S.Codeine Not Safe for Kids, Pediatricians WarnHealth Tip: Reading the Label on OTC MedicationsMylan to Offer Generic EpiPenSteep Rise in U.S. Drug Prices Tied to Patent MonopoliesSpending on Compounded Drugs Skyrocketing
Questions and AnswersVideosLinksBook Reviews
Related Topics

Anxiety Disorders
Depression: Depression & Related Conditions
Mental Disorders
Mental Health Professions

New Cholesterol Fighting Meds Target Key Gene

HealthDay News
by By Dennis ThompsonHealthDay Reporter
Updated: May 25th 2017

new article illustration

THURSDAY, May 25, 2017 (HealthDay News) -- New gene-based therapies appear to significantly decrease cholesterol levels in people, and could even cut down on arterial plaque, according to results from two early drug trials.

Both treatments improve the body's ability to break down cholesterol by targeting a specific gene that inhibits that function, researchers reported.

The angiopoietin-like 3 (ANGPTL3) gene normally restrains proteins involved in the breakdown of cholesterol, said Dr. Frederick Dewey, lead researcher of one of the trials. He is senior director and head of translational genetics at the Regeneron Genetics Center in Tarrytown, N.Y.

Two separate research groups say they've successfully reduced cholesterol in humans by using different methods to block ANGPTL3:

  • Evinacumab -- an antibody-based therapy developed by Dewey and his team -- reduced levels of triglycerides up to 76 percent and "bad" LDL cholesterol up to 23 percent in humans.
  • A new drug developed by Ionis Pharmaceuticals also caused across-the-board reductions in cholesterol, including up to 63 percent reductions in triglycerides and 33 percent reductions in LDL cholesterol.

This new method of cholesterol lowering differs from widely used statin medications, which work by inhibiting the liver's ability to produce cholesterol.

"Because this medication clears cholesterol in a way that's different, it presents another option for patients who do not respond to statins," Dewey said.

The two research efforts are exploring a field that "has been ripe for study for some time," said Dr. Robert Eckel, an American Heart Association spokesman and chair of atherosclerosis at the University of Colorado School of Medicine.

"The clinical trial data really gives some promise that we have another mechanism for use in humans," said Eckel, who wasn't involved with the studies.

However, Eckel noted that new drugs targeting ANGPTL3 likely will be expensive, given that other new cholesterol-lowering drugs have been pricey compared to generic statin medications.

He also added that clinical trials have not yet shown that drugs targeting ANGPTL3 will result in fewer strokes, heart attacks and cases of heart disease.

"We need outcome trials, and we also need to know how it competes with existing therapies and how expensive the drug will be," Eckel said.

Regeneron Pharmaceuticals started its research by looking at people with genetic mutations that caused their ANGPTL3 gene to not function properly, Dewey said.

Analysis of nearly 189,000 people revealed that people with malfunctioning ANGPTL3 genes tended to have lower cholesterol levels, as well as reduced risk of heart disease, researchers report.

"Individuals who carry these mutations that reduce the abundance of ANGPTL3 by approximately one-half had an approximate 40 percent lowering in their risk of coronary disease, which suggests there is a cardio-protective effect from inhibition of this gene," Dewey said.

Going a step further, animal studies showed that mice with high cholesterol who had their ANGPTL3 genes blocked wound up with a 40 percent reduction in arterial plaques, Dewey continued.

Based on these results, Regeneron created evinacumab as a means of blocking ANGPTL3 in people. Early clinical trials involving 83 participants showed that the antibody reduced cholesterol levels during 12 weeks of treatment, with no serious side effects, Dewey reported.

Ionis Pharmaceuticals, based in Carlsbad, Calif., is also attempting to reduce cholesterol by targeting ANGPTL3, using its own specially developed drug. The research team working with Ionis reported that after six weeks of treatment, 44 human subjects had lower cholesterol levels. Their levels slowly returned to normal after treatment ceased.

The Ionis trial also showed no serious side effects. No one in either trial had to drop out due to health problems caused by the therapies.

Regeneron has completed a phase 2 clinical trial of evinacumab and is planning phase 3 trials, which focus on the drug's effectiveness, company spokeswoman Alexandra Bowie said.

Results of both trials were published May 24 in the New England Journal of Medicine.

More information

For more on cholesterol-lowering drugs, visit the American Heart Association.